Acadian Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.7M | Buy |
1,918,063
+122,471
| +7% | +$800K | 0.01% | 553 |
|
|
2026
Q1 | $12.4M | Sell |
1,795,592
-614,822
| -26% | -$4.74M | 0.02% | 472 |
|
|
2025
Q4 | $21.3M | Buy |
2,410,414
+181,670
| +8% | +$1,000K | 0.03% | 327 |
|
|
2025
Q3 | $11.1M | Buy |
2,228,744
+496,854
| +29% | +$2.3M | 0.02% | 455 |
|
|
2025
Q2 | $8.17M | Sell |
1,731,890
-155,159
| -8% | -$678K | 0.02% | 473 |
|
|
2025
Q1 | $8.66M | Sell |
1,887,049
-12,953
| -0.7% | -$60.4K | 0.02% | 361 |
|
|
2024
Q4 | $9.1M | Hold |
1,900,002
| – | – | 0.03% | 383 |
|
|
2024
Q3 | $8.91M | Sell |
1,900,002
-82,025
| -4% | -$440K | 0.03% | 367 |
|
|
2024
Q2 | $11.2M | Sell |
1,982,027
-388,308
| -16% | -$2.01M | 0.03% | 325 |
|
|
2024
Q1 | $9.74M | Buy |
2,370,335
+107,203
| +5% | +$429K | 0.03% | 307 |
|
|
2023
Q4 | $9.54M | Buy |
2,263,132
+512,477
| +29% | +$2.07M | 0.04% | 298 |
|
|
2023
Q3 | $7.56M | Buy |
1,750,655
+611,564
| +54% | +$3.4M | 0.03% | 342 |
|
|
2023
Q2 | $7.5M | Buy |
1,139,091
+100,249
| +10% | +$643K | 0.03% | 356 |
|
|
2023
Q1 | $7.05M | Buy |
1,038,842
+320,482
| +45% | +$2.25M | 0.03% | 373 |
|
|
2022
Q4 | $5.3M | Buy |
718,360
+82,443
| +13% | +$803K | 0.03% | 426 |
|
|
2022
Q3 | $6.28M | Buy |
635,917
+608,146
| +2,190% | +$6.42M | 0.03% | 356 |
|
|
2022
Q2 | $303K | Sell |
27,771
-348,296
| -93% | -$3.61M | ﹤0.01% | 1102 |
|
|
2022
Q1 | $4.25M | Sell |
376,067
-53,713
| -12% | -$706K | 0.02% | 497 |
|
|
2021
Q4 | $6.74M | Sell |
429,780
-87,819
| -17% | -$1.53M | 0.03% | 392 |
|
|
2021
Q3 | $8.87M | Sell |
517,599
-87,239
| -14% | -$1.53M | 0.03% | 335 |
|
|
2021
Q2 | $13M | Sell |
604,838
-347,639
| -36% | -$6.22M | 0.05% | 277 |
|
|
2021
Q1 | $14.3M | Sell |
952,477
-39,202
| -4% | -$635K | 0.06% | 270 |
|
|
2020
Q4 | $13M | Sell |
991,679
-96,214
| -9% | -$1.16M | 0.05% | 291 |
|
|
2020
Q3 | $10.5M | Buy |
1,087,893
+17,627
| +2% | +$188K | 0.04% | 304 |
|
|
2020
Q2 | $12.2M | Sell |
1,070,266
-96,502
| -8% | -$1.09M | 0.05% | 295 |
|
|
2020
Q1 | $12.1M | Buy |
1,166,768
+181,251
| +18% | +$2.25M | 0.07% | 224 |
|
|
2019
Q4 | $16.2M | Buy |
985,517
+170,455
| +21% | +$2.58M | 0.07% | 234 |
|
|
2019
Q3 | $10.8M | Buy |
815,062
+259,792
| +47% | +$3.62M | 0.05% | 326 |
|
|
2019
Q2 | $7.82M | Sell |
555,270
-71,017
| -11% | -$1.13M | 0.04% | 316 |
|
|
2019
Q1 | $11.5M | Buy |
626,287
+181,237
| +41% | +$4.13M | 0.05% | 271 |
|
|
2018
Q4 | $11.6M | Buy |
445,050
+247,639
| +125% | +$5.82M | 0.06% | 245 |
|
|
2018
Q3 | $4.53M | Buy |
197,411
+152,137
| +336% | +$3.11M | 0.02% | 396 |
|
|
2018
Q2 | $862K | Buy |
+45,274
| New | +$757K | ﹤0.01% | 770 |
|
|
2017
Q3 | – | Sell |
-9,399
| Closed | -$154K | – | 1545 |
|
|
2017
Q2 | $154K | Sell |
9,399
-540,907
| -98% | -$7.8M | ﹤0.01% | 981 |
|
|
2017
Q1 | $7.7M | Sell |
550,306
-820,349
| -60% | -$11.7M | 0.04% | 337 |
|
|
2016
Q4 | $21.9M | Buy |
1,370,655
+912,371
| +199% | +$14.7M | 0.11% | 179 |
|
|
2016
Q3 | $7.63M | Buy |
458,284
+308,595
| +206% | +$4.15M | 0.04% | 306 |
|
|
2016
Q2 | $1.68M | Buy |
149,689
+138,544
| +1,243% | +$1.34M | 0.01% | 550 |
|
|
2016
Q1 | $93K | Buy |
+11,145
| New | +$91.5K | ﹤0.01% | 1035 |
|
|
2015
Q4 | – | Sell |
-1,039
| Closed | -$12K | – | 1517 |
|
|
2015
Q3 | $12K | Buy |
+1,039
| New | +$12.7K | ﹤0.01% | 1103 |
|
Other funds holding VNDA
VCM
ACM
VPM
Acadian Asset Management's VNDA Position: Q2 2026 in Review
Acadian Asset Management increased its Vanda Pharmaceuticals (VNDA) stake by 6.8% in Q2 2026, buying an estimated $800K and bringing the position to 1,918,063 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #553.
Acadian Asset Management first reported a position in VNDA in Q3 2015 and has held it in 40 quarters since. The position peaked at $21.9M in Q4 2016. 120 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.
- Acadian Asset Management held 1,918,063 shares of Vanda Pharmaceuticals worth $11.7M as of Q2 2026.
- Acadian Asset Management bought 122,471 Vanda Pharmaceuticals shares in Q2 2026, an estimated $800K.
- Vanda Pharmaceuticals made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #553 holding.
- Acadian Asset Management first reported a position in Vanda Pharmaceuticals in Q3 2015 and has held it in 40 quarters since.
- Acadian Asset Management's Vanda Pharmaceuticals position peaked at $21.9M in Q4 2016.
- 120 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.